@article{ATM19685,
author = {Marc Buyse and Tomasz Burzykowski and Everardo D. Saad},
title = {The search for surrogate endpoints for immunotherapy trials},
journal = {Annals of Translational Medicine},
volume = {6},
number = {11},
year = {2018},
keywords = {},
abstract = {Mushti and colleagues from the Food and Drug Administration (FDA) have used patient-level data from 13 trials comparing immunotherapeutic agents with standard treatment in various cancer types in an attempt to validate objective response (OR) and progression-free survival (PFS) as surrogate endpoints for overall survival (OS) (1). This is an important issue, given the current and future role of immunotherapy in several cancer types.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/19685}
}